Evidence map›Paper›PMID 37642541›Full record

ArticleBrain : a journal of neurology2024

Prognostic value of single-subject grey matter networks in early multiple sclerosis.

Vinzenz Fleischer, Gabriel Gonzalez-Escamilla, Deborah Pareto, Alex Rovira, Jaume Sastre-Garriga, Piotr Sowa, Einar A Høgestøl, Hanne F Harbo, Barbara Bellenberg, Carsten Lukas and 13 more

Abstract readMulticenter Study
In one paragraph

Article in Brain : a journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Vinzenz FleischerDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Gabriel Gonzalez-EscamillaDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Deborah ParetoSection of Neuroradiology, Department of Radiology (IDI), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Alex RoviraSection of Neuroradiology, Department of Radiology (IDI), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.ORCID 0000-0002-2132-6750
Jaume Sastre-GarrigaDepartment of Neurology/Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.ORCID 0000-0002-1589-2254
Piotr SowaDivision of Radiology and Nuclear Medicine, Oslo University Hospital, 0424 Oslo, Norway.
Einar A HøgestølInstitute of Clinical Medicine, University of Oslo, NO-0316 Oslo, Norway.ORCID 0000-0001-8446-2111
Hanne F HarboInstitute of Clinical Medicine, University of Oslo, NO-0316 Oslo, Norway.
Barbara BellenbergInstitute of Neuroradiology, St Josef Hospital, Ruhr-University Bochum, 44791 Bochum, Germany.
Carsten LukasInstitute of Neuroradiology, St Josef Hospital, Ruhr-University Bochum, 44791 Bochum, Germany.
Serena RuggieriDepartment of Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.
Claudio GasperiniDepartment of Neurosciences, San Camillo-Forlanini Hospital, 00152 Rome, Italy.
Tomas UherDepartment of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, 121 08 Prague, Czech Republic.ORCID 0000-0003-3160-9022
Manuela VaneckovaDepartment of Radiology, First Faculty of Medicine, Charles University and General University Hospital, 121 08 Prague, Czech Republic.ORCID 0000-0002-8784-7997
Stefan BittnerDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.ORCID 0000-0003-2179-3655
Ahmed E OthmanDepartment of Neuroradiology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Sara ColloroneDepartment of Neuroinflammation, Queen Square MS Centre, UCL Queen Square Institute of Neurology, Faculty of Brain Science, University College of London, WC1E 6BT London, UK.ORCID 0000-0003-1506-8983
Ahmed T ToosyDepartment of Neuroinflammation, Queen Square MS Centre, UCL Queen Square Institute of Neurology, Faculty of Brain Science, University College of London, WC1E 6BT London, UK.ORCID 0000-0002-4441-3750
Sven G MeuthDepartment of Neurology, Medical Faculty, Heinrich-Heine-University, 40225 Düsseldorf, Germany.
Frauke ZippDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.ORCID 0000-0002-1231-1928
Frederik BarkhofDepartment of Neuroinflammation, Queen Square MS Centre, UCL Queen Square Institute of Neurology, Faculty of Brain Science, University College of London, WC1E 6BT London, UK.
Olga CiccarelliDepartment of Neuroinflammation, Queen Square MS Centre, UCL Queen Square Institute of Neurology, Faculty of Brain Science, University College of London, WC1E 6BT London, UK.
Sergiu GroppaDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.

Funding

Deutsche Forschungsgemeinschaftinstitutional support of the hospital researchInstituto de Salud Carlos IIIMedical Research Council MR/S026088/1National MS SocietyNovartis Pharma GmbHRochethe Research Council
6 · The paper itself

Abstract

The identification of prognostic markers in early multiple sclerosis (MS) is challenging and requires reliable measures that robustly predict future disease trajectories. Ideally, such measures should make inferences at the individual level to inform clinical decisions. This study investigated the prognostic value of longitudinal structural networks to predict 5-year Expanded Disability Status Scale (EDSS) progression in patients with relapsing-remitting MS (RRMS). We hypothesized that network measures, derived from MRI, outperform conventional MRI measurements at identifying patients at risk of developing disability progression. This longitudinal, multicentre study within the Magnetic Resonance Imaging in MS (MAGNIMS) network included 406 patients with RRMS (mean age = 35.7 ± 9.1 years) followed up for 5 years (mean follow-up = 5.0 ± 0.6 years). EDSS was determined to track disability accumulation. A group of 153 healthy subjects (mean age = 35.0 ± 10.1 years) with longitudinal MRI served as controls. All subjects underwent MRI at baseline and again 1 year after baseline. Grey matter atrophy over 1 year and white matter lesion load were determined. A single-subject brain network was reconstructed from T1-weighted scans based on grey matter atrophy measures derived from a statistical parameter mapping-based segmentation pipeline. Key topological measures, including network degree, global efficiency and transitivity, were calculated at single-subject level to quantify network properties related to EDSS progression. Areas under receiver operator characteristic (ROC) curves were constructed for grey matter atrophy and white matter lesion load, and the network measures and comparisons between ROC curves were conducted. The applied network analyses differentiated patients with RRMS who experience EDSS progression over 5 years through lower values for network degree [H(2) = 30.0, P < 0.001] and global efficiency [H(2) = 31.3, P < 0.001] from healthy controls but also from patients without progression. For transitivity, the comparisons showed no difference between the groups [H(2) = 1.5, P = 0.474]. Most notably, changes in network degree and global efficiency were detected independent of disease activity in the first year. The described network reorganization in patients experiencing EDSS progression was evident in the absence of grey matter atrophy. Network degree and global efficiency measurements demonstrated superiority of network measures in the ROC analyses over grey matter atrophy and white matter lesion load in predicting EDSS worsening (all P-values < 0.05). Our findings provide evidence that grey matter network reorganization over 1 year discloses relevant information about subsequent clinical worsening in RRMS. Early grey matter restructuring towards lower network efficiency predicts disability accumulation and outperforms conventional MRI predictors.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingAdultAtrophyBrainDisease ProgressionGray MatterHumansMagnetic Resonance ImagingMiddle AgedPrognosisYoung Adultbrain network measuresEDSS progression in MSgraph theoryrelapsing-remitting multiple sclerosisstructural covariance

Identifiers

PMID37642541
PMCPMC10766234

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.